| 國立臺灣大學 |
2001 |
Tumor necrosis factor-induced activation of downstream NF-kB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion: Involvement of PKC, tyrosine kinase and IKK2, but not MAPKs
|
Chen, Ching-Chow; Chou, Chian-Ying; Sun, Yi-Tao; Huang, Wei-Chien |
| 國立成功大學 |
2021-07 |
Tumor Necrosis with Adjunction of Preoperative Monocyte-to-Lymphocyte Ratio as a New Risk Stratification Marker Can Independently Predict Poor Outcomes in Upper Tract Urothelial Carcinoma
|
Lin;Kun-Che;Jan;Hau-Chern;Hu;Che-Yuan;Ou;Yin-Chien;Kao;Yao-Lin;Yang;Wen-Horng;Ou;Chien-Hui |
| 國立臺灣大學 |
2007-11 |
Tumor necrotizing factor-a and GST-T1 genotype predict skin allergy to chromate in cement workers in Taiwan
|
Wang, BJ; Shiao, JSC; Chen, CJ; Lee, YC; Guo, YL |
| 臺大學術典藏 |
2019-03-04T08:13:58Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin, Shu Yung;Yang, Ching Yao;Bin-Chi Liao;Chao-Chi Ho;Wei-Yu Liao;Chen, Kuan-Yu;Tsai, Tzu Hsiu;Chia-Lin Hsu;Hsu, Wei Hsun;Kang-Yi Su;Yih-Leong Chang;Lee, Jih Hsiang;Lin, Chia Chi;Jin-Yuan Shih;Yang, James Chih Hsin;Chong-Jen Yu; Lin, Shu Yung; Yang, Ching Yao; BIN-CHI LIAO; CHAO-CHI HO; WEI-YU LIAO; Chen, Kuan-Yu; Tsai, Tzu Hsiu; CHIA-LIN HSU; Hsu, Wei Hsun; KANG-YI SU; YIH-LEONG CHANG; Lee, Jih Hsiang; Lin, Chia Chi; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:08Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Wei-Yu Liao;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; WEI-YU LIAO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:25:17Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Liao W.-Y.; Ho C.-C.; Liao B.-C.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Yang J.C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:21Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; Tsai T.-H.; Chen K.-Y.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Yu C.-J.; Yang J.C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:41Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Chao-Chi Ho;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yang J.C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Chen K.-Y.; Liao W.-Y.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2018 |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Chia-Lin Hsu;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Anonymous |
| 臺大學術典藏 |
2021-07-13T06:04:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-31T03:33:45Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
SHU-YUNG LIN; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:54Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; KUAN-YU CHEN; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:05Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-05-17T06:30:09Z |
Tumor promoter phorbol ester reversibly modulates tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3 alpha in A431 cells
|
Shiaw-Der Yang; Jau-Song Yu; Zin-Der Wen |
| 中山醫學大學 |
1998 |
Tumor promoting effect of N-nitroso-N-(2-hexanonyl)-3'-nitrotyramine (a nitrosated Maillard reaction product) in benzo(a)pyrene-initiated mouse skin carcinogenesis.
|
Tseng, TH; Chang, MC; Hsu, JD; Lee, MJ; Hsu, CL; Lan, KP; Wang, CJ |
| 中山醫學大學 |
1998 |
Tumor promotion in mouse skin by N-nitroso-N-(2-hexanonyl)-3’-nityrotyramine (a nitrosated Maillard reaction product)
|
Wang, Chau-Jong |
